Also, ACE2 inhibits the VEGFa/VGFR2/ERK1 pathway in both lung and breast cancer cells, which reduces the angiogenic potential of the cells in both cases (Feng et al., 2010; Zhang et al., 2019). Here, VEGFA is linked to breast carcinoma.